Logo

Novartis Presents Results of Beovu (brolucizumab -dbll) in P-III KESTREL and KITE Studies for Diabetic Macular Edema at ARVO2021

Share this

Novartis Presents Results of Beovu (brolucizumab -dbll) in P-III KESTREL and KITE Studies for Diabetic Macular Edema at ARVO2021

Shots:

  • The company reported the 1yrs. results from the P-III KESTREL & KITE studies assessing Beovu (6mg) vs aflibercept (2mg) in 926 patients with DME across 36 countries
  • Results: met its 1EPs i.e. non-inferiority in mean change BCVA from baseline @48wks.- patients treated with Beovu (6mg) experienced fluid (IRF/SRF) resolution and achieved CSFT levels below 280 μm @32 & 52 wks.- was well-tolerated safety in both studies
  • Novartis is committed to bring Beovu (6mg) to DME patients and will submit the data from both trails to global health authorities in H1’21 while the company anticipates 2yrs. results in late 2021

  Ref: PRnewswire | Image: Novartis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions